In our recent SPS 2022 hosted session, we discussed the Translational Assessment of Pressor Effects of Drugs with Dr.Christine Garnett (FDA), Dr.Todd Wisialowski (Pfizer) and Dr.Brian Roche (Charles River).
They presented a short overview of their work before participating in the discussion and sharing their expertise on pressure liabilities in drug development.
This document summarizes some of the key points that were explored and offers additional resources and considerations for IND-enabling studies. It will first explore clinical drivers for blood pressure assessment before reviewing preclinical translational considerations
By browsing this website, you accept the use of cookies for statistical purposes.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.
